Condition: Hepatitis b Virus · Hepatitis B · Sponsor: Rockefeller University
This is a first-in-human, placebo-controlled, single dose, dose-escalation phase 1 study to evaluate the safety, pharmacokinetics and antiviral activity of a highly potent neutralizing anti-HBV monoclonal antibody (mAb), HepB mAb19, which targets the S-protein in individuals with chronic hepatitis B (CHB) on nucleos(t)ide analog therapy (NRTI).
This description comes directly from the study's public registry record.
Recruitment Specialist · 800-782-2737 · rucares@rockefeller.edu
Marina Caskey, MD · 212-327-7396 · mcaskey@rockefeller.edu
Always discuss trial participation with your own doctor first.
| NYU Langone Health | New York, New York, United States | Recruiting |
| The Rockefeller University | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05856890